AMAbiotics

Amabiotics is a biopharmaceutical company that develops innovative microbiome-derived medicines to fight age-related diseases. Our research focuses on Gut-Brain axis pathologies. The leading drug candidate, AMA-101, is a potential first-in-class therapy for Parkinson’s disease.

 

 

Focus area
Diagnostics
Microbiome
Neuroscience
Therapeutics
Commencement date
07/01/2018